DEF 14C: Impact BioMedical Approves 2023 Equity Incentive Plan

Impact BioMedical Inc. announces the approval of its 2023 Equity Incentive Plan, reserving up to 5 million common shares for employee and director compensation.

Summary

• Impact BioMedical Inc. (the Company) has approved its 2023 Equity Incentive Plan (the 2023 Plan) by unanimous written consent of the Board of Directors and majority stockholders.
• The 2023 Plan authorizes the reservation of up to 5,000,000 shares of the Company's Common Stock for issuance, representing approximately 29.09% of issued and outstanding Common Stock as of the Record Date.
• The purpose of the 2023 Plan is to attract, motivate, and retain key service providers, align their interests with stockholders, and encourage long-term business growth.
• The Corporate Actions will become effective no sooner than 20 days after the definitive Information Statement is distributed to shareholders, expected on or about September 2, 2025.
• The Company incurred approximately $357,000 in general and administrative costs passed through from DSS, a related party, in 2024, compared to $144,000 in 2023.
• A Revolving Promissory Note with DSS, a related party, had an outstanding balance of $8,878,000 (net of fair value change of $5,068,000) as of December 31, 2024, down from $12,074,000 at December 31, 2023.
• The note's terms were amended on July 24, 2024, to allow equity payments, adjust interest to WSJ Prime Rate + 0.50%, and reclassify a significant portion from current to long-term liability.
• For the fiscal year ended December 31, 2024, the Company awarded 880,000 option grants with a purchase price of $3.00 per share under the 2023 Plan, fair valued at approximately $50,000, resulting in a stock-based compensation expense of $19,000.
• New employment agreements for CEO Frank D. Heuszel and COO Mark Suseck were effective in late 2024, detailing increased salaries and mandatory bonuses for the CEO, and stock options for both.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. The approval of the equity incentive plan is a positive step for talent retention and alignment. The reclassification of a significant portion of the related party note payable from current to long-term is also a positive financial development. However, the potential dilution from the equity plan and increased related party G&A costs temper the overall positive outlook.

Positives

• The 2023 Equity Incentive Plan is designed to attract, motivate, and retain key employees, consultants, and directors, which is crucial for long-term success and growth.
• The plan aligns the interests of participants with stockholders by tying incentives to the performance of the Company's Common Stock.
• The reclassification of a significant portion of the Revolving Promissory Note with DSS from current to long-term liability ($12,074,000 in 2023 to $7,971,000 long-term in 2024) improves the Company's short-term liquidity profile.
• The Company has established robust corporate governance structures, including Audit, Compensation, and Nominating and Corporate Governance Committees, and adopted a Code of Business Conduct and Ethics.

Negatives

• The authorization of up to 5,000,000 new shares for the 2023 Plan represents approximately 29.09% dilution to current stockholders, which could negatively impact per-share value.
• General and administrative costs passed through from related party DSS increased from $144,000 in 2023 to $357,000 in 2024.

Risks

• Potential dilution of existing shareholder value due to the issuance of up to 5,000,000 shares under the 2023 Equity Incentive Plan.
• Reliance on related party financing (Revolving Promissory Note with DSS) and ongoing related party transactions for general and administrative costs.
• Forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual outcomes and results to differ materially from forecasts.

Future Outlook

The 2023 Equity Incentive Plan is intended to provide a sufficient number of shares to satisfy equity grant requirements until the Company's 2026 annual meeting of stockholders, based on current equity incentive programs and expected grant rates. The Company aims to continue attracting and retaining key talent and aligning their interests with long-term stockholder value creation.

Management Comments

• "We are not asking you for a proxy and you are not requested to send us a proxy."
• "This is not a notice of a meeting of stockholders and no stockholders meeting will be held to consider any matter described herein."
• "The written consent that we received constitutes the only stockholder approval required for the Corporate Actions under Nevada law and the Company’s Certificate of Incorporation and Bylaws."
• "No further action by any other stockholder is required to approve the Corporate Actions and we have not and will not be soliciting your approval of the Corporate Actions."

Industry Context

The approval of an equity incentive plan is a standard corporate governance practice across industries, particularly in growth-oriented sectors like biomedical, to attract and retain top talent. Such plans are essential for aligning employee and executive incentives with long-term company performance and shareholder value creation, a common strategy in competitive talent markets.

Comparison to Industry Standards

• The 2023 Equity Incentive Plan's reservation of up to 5,000,000 shares, representing approximately 29.09% of outstanding common stock, is a notable percentage for an equity plan. While specific industry benchmarks vary, this level of potential dilution should be evaluated against peer companies' typical equity compensation pools to assess its competitiveness and potential impact on existing shareholders.
• The structure of executive compensation, including base salary, mandatory bonuses, and stock options, aligns with common practices in the biomedical sector, aiming to incentivize long-term performance. For example, the CEO's base salary increasing from $200,000 to $250,000 over three years, coupled with mandatory bonuses, reflects a structured approach to executive remuneration.
• The establishment of independent Audit, Compensation, and Nominating and Corporate Governance Committees, with members meeting NYSE American independence standards, demonstrates adherence to best practices in corporate governance, comparable to well-governed public companies across various industries.

Corporate Governance

Related Party Transactions

• The GRDG Agreement, which involved the Company funding scientific operations of GRDG (a minority stockholder of two Company subsidiaries), ended in September 2023. Expenses incurred were $25,000 in 2024 and $447,000 in 2023.
• General and administrative costs incurred by DSS, a related party, on behalf of the Company are passed through monthly. These costs were approximately $31,000 per month from January to September 2024, and $26,000 per month from October 2024. Total related expenses were $357,000 in 2024 and $144,000 in 2023.
• A Revolving Promissory Note with DSS, a related party, was executed on December 31, 2020, and amended on July 24, 2024 (effective September 16, 2024). The amendment allows for principal/interest payments in exchange for potential equity, changed quarterly interest due dates, adjusted the 'On Demand' feature, continued a planned repayment program, and adjusted the interest rate to WSJ Prime Rate plus 0.50%.
• The outstanding balance of the Revolving Promissory Note with DSS was $8,878,000 (net of fair value change of $5,068,000) as of December 31, 2024, and $12,074,000 as of December 31, 2023. The 2024 balance includes $35,000 in current portion and $7,971,000 in long-term portion, a significant reclassification from 2023 where the entire $12,074,000 was current.

Stakeholder Impact

• **Shareholders**: Potential dilution from the 5,000,000 shares reserved for the equity incentive plan (approx. 29.09% of outstanding common stock). However, the plan aims to align management interests with long-term shareholder value.
• **Employees/Management**: The 2023 Equity Incentive Plan provides a mechanism for equity-based compensation, which can serve as a strong incentive for attraction, motivation, and retention of key talent.
• **Creditors (DSS)**: The amendment to the Revolving Promissory Note allows for potential equity payments, which could alter the nature of repayment for DSS. The reclassification of a significant portion of the note to long-term improves the Company's short-term financial flexibility.

Next Steps

• The definitive Information Statement materials will be mailed to stockholders on or about August 13, 2025.
• The Corporate Actions, including the 2023 Equity Incentive Plan, will become effective no sooner than 20 days after the definitive Information Statement has been distributed to shareholders, expected on or about September 2, 2025.
• The 2023 Plan is intended to provide sufficient shares for equity grants until the Company's 2026 annual meeting of stockholders.

Key Dates

Recommendation

The filing is a procedural information statement regarding the approval of an equity incentive plan and corporate governance updates, not a financial performance report. While the equity plan is a positive for long-term talent retention and the reclassification of related party debt to long-term is favorable for liquidity, there is no new operational or financial data to warrant a change in investment stance. The potential dilution from the equity plan is a factor to monitor. Therefore, a 'hold' recommendation is appropriate as investors should await further financial and operational updates before making a more definitive decision.

Keywords

Equity Incentive Plan, Stock Options, Corporate Governance, SEC Filing, DEF 14C, Biomedical, Executive Compensation, Related Party Transactions, Shareholder Dilution, Nevada Corporation